Results 71 to 80 of about 7,834 (208)

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2 Japanese Subgroup Analysis

Cancer Medicine
Background In TALAPRO‐2, the poly(ADP‐ribose) polymerase inhibitor talazoparib plus the androgen receptor–signaling inhibitor enzalutamide improved radiographic progression‐free survival (rPFS) versus placebo plus enzalutamide (hazard ratio [HR] = 0.63 ...
Nobuaki Matsubara, Hideaki Miyake, Hiroji Uemura, Atsushi Mizokami, Hiroaki Kikukawa, Takeo Kosaka, Kazuo Nishimura, Motonobu Nakamura, Kazuki Kobayashi, Atsushi Komaru, Yuko Mori, Shigeyuki Toyoizumi, Natsuki Hori, Yoshiko Umeyama, Hirotsugu Uemura   +14 more
doaj   +1 more source

Effect and Safety of Therapeutic Regimens for Patients With Germline BRCA Mutation-Associated Breast Cancer: A Network Meta-Analysis

Frontiers in Oncology, 2021
PurposeBreast cancer type 1 susceptibility (BRCA) mutations not only increase breast cancer (BC) risk but also result in poor survival and prognosis for BC patients.
Ying Jiang, Xiang-Yu Meng, Ning-Ning Deng, Chen Meng, Lu-Hui Li, Zi-Kang He, Xing-Yun Wang, Zhe-Yao Song, Rong-Jun Cui   +8 more
doaj   +1 more source

Triple Negative Breast Cancer - Review of Current and Emerging Therapeutic Strategies [PDF]

, 2016
Triple negative breast cancer (TNBC) is associated with a poor prognosis compared to other types of breast cancer. The classification of 'triple negative' is not one homogenous tumor type, but rather is made up of multiple molecularly and biologically ...
Ballinger, Tarah, Kremer, Jill, Miller, Kathy   +2 more
core   +1 more source

Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression

Advanced Science, EarlyView.
Pancreatic neuroendocrine tumors frequently silence MEN1 through epigenetic mechanisms. Here, SIRT7 recruits DNMT1 to the MEN1 promoter, drives hypermethylation, and enhances DNA repair. Inhibiting SIRT7 restores MEN1, reduces MRN complex abundance, impairs double‐strand break repair, and sensitizes PanNET models to radiation, supporting SIRT7 as a ...
Jianyun Jiang, Yan Wang, Yi Qin, Luohai Chen, Xiaowu Xu, Guixiong Fan, Desheng Jing, Miaoyan Wei, Xianjun Yu, Junfeng Xu, Shunrong Ji, Jie Chen   +11 more
wiley   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies

Drug Design, Development and Therapy, 2020
Mohamed W Attwa, 1, 2 Adnan A Kadi, 1 Ali S Abdelhameed, 1 Hassan A Alhazmi 3, 4 1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; 2Students’ University Hospital, Mansoura University ...
Attwa MW, Kadi AA, Abdelhameed AS, Alhazmi HA   +3 more
doaj  

Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer

Медицинский совет, 2020
Introduction. The presence of a germinal BRCA mutation occurs in 3–4% of all breast cancer (BC) patients with various biological subtypes, but significantly with a high frequency in patients with a triple negative biological subtype (in 10–20% of cases).
T. Yu. Semiglazova, E. V. Lubennikova, L. V. Bolotina, R. V. Orlova, F. V. Moiseenko, A. V. Avramenko, E. V. Artemeva, S. A. Borozdina, A. A. Vakhitova, N. M. Volkov, I. P. Ganshina, Sh. A. Dzhalilova, L. G. Zhukova, B. S. Kasparov, A. A. Kachmazov, V. V. Klimenko, A. i. Kornietskaya, A. A. Meshcheryakov, A. A. Paichadze, A. N. Poltoratsky, O. E. Ryabishina, M. L. Stepanova, E. N Imyanitov   +22 more
doaj   +1 more source

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations [PDF]

, 2016
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have shown clinical activity in epithelial ovarian cancer, leading both the US Food and Drug Administration (FDA) and the European Medicines Agency to approve olaparib for tumors ...
Ledermann, JA, Miller, RE
core  

Homologous recombination deficiency and ovarian cancer [PDF]

, 2016
The discovery that PARP inhibitors block an essential pathway of DNA repair in cells harbouring a BRCA mutation has opened up a new therapeutic avenue for high-grade ovarian cancers.
Drew, Y, Kristeleit, RS, Ledermann, JA
core   +1 more source

The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1. [PDF]

, 2020
The therapy of advanced mycosis fungoides (MF) presents a therapeutic challenge, and the search for new therapeutic targets is ongoing. Poly(ADP-ribose) polymerase 1 was shown to be upregulated in patients with advanced MF and could be druggable by a new
Akilov, Oleg, Hwang, Sam, Kruglov, Oleg, Wu, Xuesong   +3 more
core   +1 more source